“These results really support the view that IL-17A and IL-17F blockade as useful in psoriasis.” – Andrew Blauvelt, MD, of Oregon Medical Research Center in Portland, on a trial involving a novel biologic agent.
“These results imply that biological aging pathways may directly contribute to MS progression.” — Jennifer Graves, MD, PhD, of the University of California, San Diego, on a study of telomere length in multiple sclerosis patients.
“For the vast majority of us, we don’t use PASI, because you literally have to take out a pen and paper, do a worksheet, start doing the math and things we’ve tried to forget from elementary school.” – George Han, MD, PhD, of Mount Sinai Beth Israel Hospital in New York City, on limitations of the Psoriasis Area and Severity Index.
“Heck, Guatemala is at 56% peritoneal!” – Health and Human Services Secretary Alex Azar, on U.S. dialysis practices in end-stage renal disease.
“Absolutely worth watching.” — Paul Volberding, MD, of University of California, San Francisco, commenting on the second patient with sustained HIV remission.
“It remains to be seen whether people look back on him as someone who made very strong public statements and promises and didn’t deliver.” – Matt Myers, president of the Campaign for Tobacco-Free Kids, on the departure announcement of FDA Commissioner Scott Gottlieb, MD.
“In general, he was far better than I imagined he would be as FDA commissioner.” — Drug pricing consultant Marsha Simon, PhD, also on Gottlieb’s announced resignation.